These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 3622243)
1. Comparative in vitro evaluation of BMY-28142, a new broad-spectrum cephalosporin, versus other beta-lactams against multiresistant gram-negative isolates. Giamarellou H; Sahin A; Chryssouli Z Drugs Exp Clin Res; 1987; 13(3):149-53. PubMed ID: 3622243 [TBL] [Abstract][Full Text] [Related]
2. [Comparative antibacterial activity of a new monobactam, carumonam (RO 17-2301, AMA 1080) on hospital bacteria resistant to beta lactams]. Le Noc P; Croize J; Le Noc D Pathol Biol (Paris); 1987 May; 35(5):451-6. PubMed ID: 3302846 [TBL] [Abstract][Full Text] [Related]
3. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Jones RN; Sader HS; Fritsche TR; Pottumarthy S Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923 [TBL] [Abstract][Full Text] [Related]
4. [In vitro activity of cefmenoxime (SCE 1365) against 616 hospital strains of gram-negative bacilli chosen for beta-lactam resistance. Comparison with cefotaxime, lamoxactam and ceftazidime]. Le Noc P; Bryskier A; Le Noc D Pathol Biol (Paris); 1983 May; 31(5):351-6. PubMed ID: 6312396 [TBL] [Abstract][Full Text] [Related]
5. [Comparative in vitro activity of 2 monobactams (RO 172301 (AMA 1080)and aztreonam), ceftazidime and cefotaxime on Gram-negative bacilli]. Thabaut A; Meyran M; Huerre M Pathol Biol (Paris); 1985 May; 33(5):404-7. PubMed ID: 3929217 [TBL] [Abstract][Full Text] [Related]
6. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents. Bell JM; Turnidge JD; Pathology; 2001 Feb; 33(1):53-60. PubMed ID: 11280610 [TBL] [Abstract][Full Text] [Related]
7. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China]. Chen MJ; Wang H; Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912 [TBL] [Abstract][Full Text] [Related]
8. In vitro activity of imipenem and six other beta-lactam antibiotics against aminoglycoside resistant gram-negative bacilli. Bujdáková H; Kallová J; Lausová A; Kettner M Microbios; 1995; 84(339):87-90. PubMed ID: 8628124 [TBL] [Abstract][Full Text] [Related]
9. [In-vitro activity of ceftriaxone on Gram-negative bacilli with various resistance phenotypes to cephalosporins. Comparison with cefotaxime, cefmenoxime, moxalactam, ceftazidime]. Rouhan D; Le Noc P; Le Noc D Pathol Biol (Paris); 1986 May; 34(5):404-9. PubMed ID: 3534713 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime. Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406 [TBL] [Abstract][Full Text] [Related]
11. [Sensitivity of multiresistant bacterial strains to imipenem (Tienam)]. Ruczkowska J; Dolna I Przegl Lek; 1992; 49(5):151-3. PubMed ID: 1438917 [TBL] [Abstract][Full Text] [Related]
12. Antimicrobial resistance among gram-negative bacilli to newer aminoglycosides and beta-lactams. Jain S; Sarkar R Indian J Pathol Microbiol; 1991 Oct; 34(4):280-7. PubMed ID: 1818033 [TBL] [Abstract][Full Text] [Related]
13. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Giamarellou H Am J Med; 1986 Jun; 80(6B):126-37. PubMed ID: 3088998 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of ceftazidime and ceftriaxone. Keenholtz SL; Jacobus NV; Tally FP; Gorbach SL Clin Ther; 1983; 5(6):603-16. PubMed ID: 6313195 [TBL] [Abstract][Full Text] [Related]
15. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005]. Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265 [TBL] [Abstract][Full Text] [Related]
16. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin. Tumah H Chemotherapy; 2005 May; 51(2-3):80-5. PubMed ID: 15870501 [TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Pfaller MA; Sader HS; Fritsche TR; Jones RN Diagn Microbiol Infect Dis; 2006 Sep; 56(1):63-8. PubMed ID: 16650951 [TBL] [Abstract][Full Text] [Related]
18. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Sader HS; Fritsche TR; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569 [TBL] [Abstract][Full Text] [Related]
19. [In vitro antibacterial activity of cefodizime (HR 221) on 323 hospital strains of Gram negative bacilli. Comparison with cefotiam, cefoperazone, cefotetan and cefotaxime]. Le Noc P; Bryskier A; Le Noc D Pathol Biol (Paris); 1985 May; 33(5):399-403. PubMed ID: 3897972 [TBL] [Abstract][Full Text] [Related]
20. Antibacterial activity of moxalactam (LY-127935) compared with cefotaxime and other beta-lactam antibiotics against clinical isolates of enterobacteriacea and non-fermenters. Verbist L Arzneimittelforschung; 1981; 31(6):982-6. PubMed ID: 6266430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]